Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 21, Pages -Publisher
MDPI
DOI: 10.3390/ijms232112745
Keywords
sphingolipids; hematological malignancies; leukemia; myeloma; lymphoma; ceramide; sphingosine-1-phosphate; sphingolipid metabolism; acid ceramidase; sphingosine kinase-1
Funding
- U.S. National Institutes of Health, National Cancer Institute [P01 CA097132]
Ask authors/readers for more resources
Dysregulation of sphingolipid metabolism plays a complex role in hematological malignancies, contributing to the design of combinatorial therapeutic regimens and reducing resistance to standard therapies. Inhibitors targeting specific nodes of the sphingolipid pathway significantly decrease leukemic cell survival. The recent advances in this field focus on the latter part of the last decade.
Dysregulation of sphingolipid metabolism plays a complex role in hematological malignancies, beginning with the first historical link between sphingolipids and apoptosis discovered in HL-60 leukemic cells. Numerous manuscripts have reviewed the field including the early discoveries that jumpstarted the studies. Many studies discussed here support a role for sphingolipids, such as ceramide, in combinatorial therapeutic regimens to enhance anti-leukemic effects and reduce resistance to standard therapies. Additionally, inhibitors of specific nodes of the sphingolipid pathway, such as sphingosine kinase inhibitors, significantly reduce leukemic cell survival in various types of leukemias. Acid ceramidase inhibitors have also shown promising results in acute myeloid leukemia. As the field moves rapidly, here we aim to expand the body of literature discussed in previously published reviews by focusing on advances reported in the latter part of the last decade.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available